Immunovia AB (publ) (IMMNOV.ST)
SEK 0.28
(3.38%)
SEK 0.28
(3.38%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -7.38 SEK | -24.03% |
| 2022 | -5.95 SEK | 7.75% |
| 2021 | -6.45 SEK | -0.62% |
| 2020 | -6.41 SEK | -18.05% |
| 2019 | -5.43 SEK | -25.4% |
| 2018 | -4.33 SEK | -74.6% |
| 2017 | -2.48 SEK | -172.53% |
| 2016 | -0.91 SEK | -51.67% |
| 2015 | -0.60 SEK | 18.92% |
| 2014 | -0.74 SEK | -469.23% |
| 2013 | -0.13 SEK | -490.91% |
| 2012 | -0.02 SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.07 SEK | 93.97% |
| 2024 Q2 | -0.28 SEK | -330.11% |
| 2023 FY | - SEK | -24.03% |
| 2023 Q2 | -4.00 SEK | -66.67% |
| 2023 Q1 | -2.40 SEK | 30.03% |
| 2023 Q3 | -0.91 SEK | 77.25% |
| 2023 Q4 | -1.08 SEK | -18.68% |
| 2022 Q3 | -0.16 SEK | 76.47% |
| 2022 FY | - SEK | 7.75% |
| 2022 Q4 | -3.43 SEK | -2043.75% |
| 2022 Q2 | -0.68 SEK | 59.52% |
| 2022 Q1 | -1.68 SEK | 19.23% |
| 2021 Q3 | -1.48 SEK | 26.73% |
| 2021 Q1 | -0.96 SEK | 52.94% |
| 2021 Q2 | -2.02 SEK | -110.42% |
| 2021 FY | - SEK | -0.62% |
| 2021 Q4 | -2.08 SEK | -40.54% |
| 2020 FY | - SEK | -18.05% |
| 2020 Q1 | -1.31 SEK | 21.08% |
| 2020 Q2 | -1.55 SEK | -18.32% |
| 2020 Q4 | -2.04 SEK | -30.77% |
| 2020 Q3 | -1.56 SEK | -0.65% |
| 2019 Q2 | -1.42 SEK | -13.6% |
| 2019 Q4 | -1.66 SEK | -36.07% |
| 2019 Q1 | -1.25 SEK | 5.3% |
| 2019 FY | - SEK | -25.4% |
| 2019 Q3 | -1.22 SEK | 14.08% |
| 2018 FY | - SEK | -74.6% |
| 2018 Q4 | -1.32 SEK | -59.04% |
| 2018 Q3 | -0.83 SEK | 38.97% |
| 2018 Q1 | -0.93 SEK | -5.68% |
| 2018 Q2 | -1.36 SEK | -46.24% |
| 2017 Q1 | -0.43 SEK | -34.37% |
| 2017 FY | - SEK | -172.53% |
| 2017 Q4 | -0.88 SEK | -37.5% |
| 2017 Q3 | -0.64 SEK | -10.34% |
| 2017 Q2 | -0.58 SEK | -34.88% |
| 2016 Q3 | -0.26 SEK | -36.84% |
| 2016 Q4 | -0.32 SEK | -23.08% |
| 2016 FY | - SEK | -51.67% |
| 2016 Q2 | -0.19 SEK | -18.75% |
| 2016 Q1 | -0.16 SEK | -6.67% |
| 2015 FY | - SEK | 18.92% |
| 2015 Q4 | -0.15 SEK | 0.0% |
| 2015 Q1 | -0.17 SEK | 37.04% |
| 2015 Q3 | -0.15 SEK | 11.76% |
| 2015 Q2 | -0.17 SEK | 0.0% |
| 2014 Q4 | -0.27 SEK | -3.05% |
| 2014 Q1 | -0.12 SEK | 0.0% |
| 2014 Q2 | -0.12 SEK | -0.83% |
| 2014 Q3 | -0.26 SEK | -116.53% |
| 2014 FY | - SEK | -469.23% |
| 2013 FY | - SEK | -490.91% |
| 2012 FY | - SEK | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AroCell AB (publ) | -0.26 SEK | -2738.462% |
| Devyser Diagnostics AB (publ) | -3.31 SEK | -122.961% |
| Prostatype Genomics AB (publ) | -0.24 SEK | -2975.0% |
| SenzaGen AB | -0.91 SEK | -710.989% |
| Spermosens AB | -0.15 SEK | -4820.0% |